TerminatedPhase 1NCT01225146

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
David M. Brown, M.D.
Principal Investigator
Charles C Wykoff, MD, PhD
Retina Consultants Houston
Intervention
ranibizumab(drug)
Enrollment
8 enrolled
Eligibility
18 years · All sexes
Timeline
20102012

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01225146 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials